Last reviewed · How we verify

Tagrisso — Competitive Intelligence Brief

Tagrisso (osimertinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] ALK tyrosine kinase receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tagrisso (osimertinib) — AstraZeneca. Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tagrisso TARGET osimertinib AstraZeneca marketed Kinase Inhibitor [EPC] ALK tyrosine kinase receptor 2015-01-01
Lorbrena Lorlatinib Pfizer marketed Kinase Inhibitor [EPC] ALK tyrosine kinase receptor 2018-01-01
Lorbrena lorlatinib Pfizer marketed Kinase Inhibitor [EPC] ALK tyrosine kinase receptor 2018-01-01
Alunbrig brigatinib Takeda marketed Kinase Inhibitor [EPC] ALK tyrosine kinase receptor 2017-01-01
Alecensa alectinib Hoffmann-La Roche marketed Kinase Inhibitor ALK tyrosine kinase receptor 2015-01-01
Zykadia ceritinib Novartis marketed Kinase Inhibitor [EPC] ALK tyrosine kinase receptor 2014-01-01
Itovebi INAVOLISIB Genentech Inc marketed Kinase Inhibitor [EPC] 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Kinase Inhibitor [EPC] class)

  1. · 12 drugs in this class
  2. Pfizer · 7 drugs in this class
  3. Novartis · 3 drugs in this class
  4. Bayer · 2 drugs in this class
  5. Boehringer Ingelheim · 2 drugs in this class
  6. AstraZeneca · 2 drugs in this class
  7. Beigene Usa Inc · 1 drug in this class
  8. BeiGene · 1 drug in this class
  9. AbbVie · 1 drug in this class
  10. Bristol · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tagrisso — Competitive Intelligence Brief. https://druglandscape.com/ci/osimertinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: